Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025.

The U.S. Food and Drug Administration gave SC291, a CD19-directed allogeneic CAR T cell therapy developed using Sana's hypoimmune platform, fast track designation, a process designed to facilitate the ...

Fast Track designation is designed to expedite clinical development and regulatory review timelinesEnrolling patients in the GLEAM trial for ...

NHL Vancouver Canucks and Fortinet ® (NASDAQ: FTNT), the global cybersecurity leader driving the convergence of networking and security, today announced that Fortinet has become the new Preferred ...

Sana Biotechnology (SANA) announced that the U.S. Food and Drug Administration granted Fast Track designation for SC291 in relapsed/refractory systemic lupus erythematosus, which includes extrarenal ...

Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for ...

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by inflammation and tissue damage across multiple organ systems, such as the skin, joints, kidneys, heart, and brain.

Sana Biotechnology, Inc.'s stock has dropped, but with pipeline focus and upcoming trial data, its prospects remain mixed ...

Pomerantz LLP is investigating claims on behalf of investors of  Sana Biotechnology, Inc. ("Sana" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

[Click here for information about joining the class action] On November 4, 2024, Sana issued a press release announcing that it "will suspend development of both SC291 in oncology and of SC379 ...